Summary

Report Scope
This report provides an overview of the global biological therapies for the cancer market and analyzes market trends. It includes global revenue ($ millions) for the base year data of 2024 and estimated data for the forecast period 2025 through 2030. The market is based on technology, application, end user, and region. The regions covered in this study include North America, Europe, Asia-Pacific, the Rest of the World, focusing on major countries in these regions.
The report also sheds light on developments related to venture capital and corporate investments, regulatory trends, and the enterprise strategies of key firms as well as potential future opportunities stemming from biological therapies for cancer of precision medicine and population genomics programs. The combination of in-depth market forecasts, macroeconomic analysis, and tariff assessments makes this report a critical resource for stakeholders, investors, and policymakers seeking to understand and take advantage of the rapidly developing biological therapies for cancer sector. The report focuses on the significant driving trends and challenges that affect the market and vendor landscape. It also analyzes emerging technologies related to the market.
The report concludes with an analysis of the competitive landscape, which provides the ranking/share of key players in the biological therapies for cancer market. It also has a dedicated section of company profiles that covers the details of key market players. For market estimates, data have been provided for 2022 and 2023 as the historic years, 2024 as the base year, and 2025?2030 for the forecast years.

Report Includes
- 43 data tables and 53 additional tables
- An analysis of the global markets for biological therapies for cancer treatment and related technologies
- Analyses of the global market trends, with revenue data for 2022-2024, estimates for 2025 and projections of compound annual growth rates (CAGRs) through 2030
- Estimates of the current market size and revenue prospects for the global cancer biologics market, along with a market share analysis by product type, cancer type, and region
- Facts and figures about market dynamics, opportunities and deterrents, technological advances, regulations, innovations and standards and the impacts of macroeconomic variables
- Impact analysis of the U.S. tariff laws on the market
- Insights derived from Porter’s Five Forces model, as well as global supply chain
- A look at major issues and trends related to the R&D of more effective cancer treatment, new cancer therapeutics in development and the outlook on cancer clinical trials
- Key marketed drugs and recent approvals, sales statistics and past performance of the top-selling biologics and insight into their patent expiries
- A relevant patent analysis, featuring key granted and published patents
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
- Analysis of the industry structure, including companies’ market shares and rankings, strategic initiatives, M&A activity and a venture funding outlook
- Profiles of the leading companies, including Merck & Co. Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., AstraZeneca, and Johnson & Johnson

ページTOPに戻る

Table of Contents

Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Technological Advances
Market Dynamics and Growth Factors
Segmental Analysis
Conclusion
Chapter 2 Market Overview
Overview and Market Definition
Key Modalities and Mechanisms of Action
Porter's Five Forces Model
Bargaining Power of Buyers
Bargaining Power of Suppliers
Potential for New Entrants
Competition in the Industry
Threat of Substitutes
Macroeconomic Factors Analysis
Aging Population Driving Cancer Incidence and Demand for Biologics
Rising Healthcare Expenditures and Oncology Drug Spending
Impact of the U.S. Tariff Scenario
Pricing Strategies for Cancer Biologics
Value-Based Pricing
Premium Pricing for Innovation
Indication-Based Pricing
Market Access and Tiered Pricing
Competitive Benchmarking
Cancer Drug Costs
Overview of Biosimilars
Biosimilars and Costs of Cancer Drugs
Biosimilars in India and China
Biosimilars in Europe
Issues with Biosimilars
Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Rising Global Cancer Incidence
Advances in Immuno-Oncology and Targeted Therapies
Shift Towards Personalized and Precision Medicine
Market Restraints
High Treatment Costs
Stringent Manufacturing and Regulatory Requirements
Market Opportunities
Expanding Indications for Approved Biologics
Technological Advances in Biologics Manufacturing
Chapter 4 Regulatory Landscape
Biological Therapies for Cancer Industry Regulatory Scenario
Overview
U.S.
EU
Japan
China
India
Medicare Coverage and Reimbursement for Cancer Care
Chapter 5 Emerging Technologies and Developments
Overview
Next-Generation Antibody-Drug Conjugates (ADCs)
Bispecific and Multispecific Antibodies
Neoantigen and Personalized Cancer Vaccines (mRNA and Peptide)
Allogeneic (“Off-the-Shelf”) Cell Therapies
Artificial Intelligence (AI) in Biological Cancer Therapies
Chapter 6 Market Segmentation Analysis
Segmentation Breakdown
Market Analysis for Biological Therapies for Cancer by Product Type
Monoclonal Antibodies
Vaccines
CAR T-cell Therapy
Cancer Growth Blockers
Immune Checkpoint Inhibitors
Other (Blood Cell Growth Factors, Cytokines)
Market Analysis of Biological Therapies for Cancer by Cancer Type
Epidemiology by Cancer Type/Site
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Other (Blood, Skin, Ovarian, Rare Cancer)
Geographic Breakdown
Global Biosimilars Market by Region
Market Size and Forecast
North America
Europe
Asia-Pacific
Rest of the World
Chapter 7 Cancer Clinical Trials and Biologics in Development
Overview
Key Pipeline Drugs by Company
Chapter 8 Competitive Landscape
Overview
Biological Therapy for Cancer Market: Major Players
Chapter 9 Appendix
Methodology
References
Abbreviations
Company Profiles
AMGEN INC.
ASTRAZENECA
BAYER AG
BIONTECH SE
BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.
GSK PLC
INCYTE
INNATE PHARMA INC.
JOHNSON & JOHNSON
LILLY USA LLC
MERCK & CO. INC.
NOVARTIS AG
PFIZER INC.
SANOFI

ページTOPに戻る

List of Tables/Graphs

List of Tables
Summary Table : Global Biological Therapies Market for Cancer, by Product Type, Through 2030
Table 1 : Key Federal Health Insurance Programs in the U.S.
Table 2 : Global Biological Therapies Market for Cancer, by Product Type, Through 2030
Table 3 : Monoclonal Antibodies Approved for Oncology
Table 4 : Global Monoclonal Antibodies Therapy Market for Cancer, by Region, Through 2030
Table 5 : Global Vaccines Therapy Market for Cancer, by Region, Through 2030
Table 6 : Global CAR T-Cell Therapy Market for Cancer, by Region, Through 2030
Table 7 : Global Cancer Growth Blockers Therapy Market for Cancer, by Region, Through 2030
Table 8 : Immune Checkpoint Inhibitors Approved for Oncology
Table 9 : Global Immune Checkpoint Inhibitors Therapy Market for Cancer, by Region, Through 2030
Table 10 : Global Other Biological Therapies Market for Cancer, by Region, Through 2030
Table 11 : Global Cancer Incidence, by Cancer Type/Site, 2022
Table 12 : Global Biological Therapies Market for Cancer, by Cancer Type, Through 2030
Table 13 : Global Biological Therapies Market for Lung Cancer, by Region, Through 2030
Table 14 : Global Biological Therapies Market for Breast Cancer, by Region, Through 2030
Table 15 : Global Biological Therapies Market for Colorectal Cancer, by Region, Through 2030
Table 16 : Global Biological Therapies Market for Prostate Cancer, by Region, Through 2030
Table 17 : Global Biological Therapies Market for Other (Blood, Skin, Ovarian, Rare Cancers) Cancers, by Region, Through 2030
Table 18 : Global Biological Therapies Market for Cancer, by Region, Through 2030
Table 19 : North American Biological Therapies Market for Cancer, by Country, Through 2030
Table 20 : North American Biological Therapies Market for Cancer, by Product Type, Through 2030
Table 21 : North American Biological Therapies Market for Cancer, by Cancer Type, Through 2030
Table 22 : European Biological Therapies Market for Cancer, by Country, Through 2030
Table 23 : European Biological Therapies Market for Cancer, by Product Type, Through 2030
Table 24 : European Biological Therapies Market for Cancer, by Cancer Type, Through 2030
Table 25 : Asia-Pacific Biological Therapies Market for Cancer, by Country, Through 2030
Table 26 : Asia-Pacific Biological Therapies Market for Cancer, by Product Type, Through 2030
Table 27 : Asia-Pacific Biological Therapies Market for Cancer, by Cancer Type, Through 2030
Table 28 : Rest of the World Biological Therapies Market for Cancer, by Product Type, Through 2030
Table 29 : Rest of the World Biological Therapies Market for Cancer, by Cancer Type, Through 2030
Table 30 : Clinical Trials, by Cancer Type/Site and Phase, 2025
Table 31 : Key Pipeline Cancer Biologics
Table 32 : Sales of Blockbuster Biological Cancer Therapy Drugs, 2024
Table 33 : Leading Biological Therapies for Cancer Companies, Strategic Developments, 2024-2025
Table 34 : Information Sources for this Report
Table 35 : Abbreviations Used in this Report
Table 36 : Amgen Inc.: Company Snapshot
Table 37 : Amgen Inc.: Financial Performance, FY 2023 and 2024
Table 38 : Amgen Inc.: Product Portfolio
Table 39 : Amgen Inc.: News/Key Developments, 2024-2025
Table 40 : AstraZeneca: Company Snapshot
Table 41 : AstraZeneca: Financial Performance, FY 2023 and 2024
Table 42 : AstraZeneca: Product Portfolio
Table 43 : AstraZeneca: News/Key Developments, 2024-2025
Table 44 : Bayer AG: Company Snapshot
Table 45 : Bayer AG: Financial Performance, FY 2023 and 2024
Table 46 : Bayer AG: Product Portfolio
Table 47 : Bayer AG: News/Key Developments, 2024
Table 48 : BioNTech SE: Company Snapshot
Table 49 : BioNTech SE: Financial Performance, FY 2023 and 2024
Table 50 : BioNTech SE: Product Portfolio
Table 51 : BioNTech SE: News/Key Developments, 2024-2025
Table 52 : Bristol-Myers Squibb Co.: Company Snapshot
Table 53 : Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024
Table 54 : Bristol-Myers Squibb Co.: Product Portfolio
Table 55 : Bristol-Myers Squibb Co.: News/Key Developments, 2024-2025
Table 56 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 57 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
Table 58 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 59 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2024-2025
Table 60 : Gsk Plc: Company Snapshot
Table 61 : Gsk Plc: Financial Performance, FY 2023 and 2024
Table 62 : Gsk Plc.: Product Portfolio
Table 63 : Gsk Plc.: News/Key Developments, 2024-2025
Table 64 : Incyte: Company Snapshot
Table 65 : Incyte: Financial Performance, FY 2023 and 2024
Table 66 : Incyte: Product Portfolio
Table 67 : Incyte: News/Key Developments, 2025
Table 68 : Innate Pharma Inc.: Company Snapshot
Table 69 : Innate Pharma Inc.: Financial Performance, FY 2023 and 2024
Table 70 : Innate Pharma Inc.: Product Portfolio
Table 71 : Innate Pharma Inc.: News/Key Developments, 2024-2025
Table 72 : Johnson & Johnson: Company Snapshot
Table 73 : Johnson & Johnson: Financial Performance, FY 2023 and 2024
Table 74 : Johnson & Johnson: Product Portfolio
Table 75 : Johnson & Johnson: News/Key Developments, 2025
Table 76 : Lilly USA LLC: Company Snapshot
Table 77 : Lilly USA LLC: Financial Performance, FY 2023 and 2024
Table 78 : Lilly USA LLC: Product Portfolio
Table 79 : Lilly USA LLC: News/Key Developments, 2023-2024
Table 80 : Merck & Co. Inc.: Company Snapshot
Table 81 : Merck & Co. Inc.: Financial Performance, FY 2023 and 2024
Table 82 : Merck & Co. Inc.: Product Portfolio
Table 83 : Merck & Co. Inc.: News/Key Developments, 2024-2025
Table 84 : Novartis AG: Company Snapshot
Table 85 : Novartis AG: Financial Performance, FY 2023 and 2024
Table 86 : Novartis AG: Product Portfolio
Table 87 : Novartis AG: News/Key Developments, 2024-2025
Table 88 : Pfizer Inc.: Company Snapshot
Table 89 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
Table 90 : Pfizer Inc.: Product Portfolio
Table 91 : Pfizer Inc.: News/Key Developments, 2025
Table 92 : Sanofi: Company Snapshot
Table 93 : Sanofi: Financial Performance, FY 2023 and 2024
Table 94 : Sanofi: Product Portfolio
Table 95 : Sanofi: News/Key Developments, 2024-2025